OTR Therapeutics, a biotechnology company focused on turning early-stage innovations into impactful global therapies, and Zealand Pharma, a leader in metabolic health, announced a multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases.
The partnership combines Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics’ proprietary R&D platform, recognized for speed, efficiency, and quality, along with strong regional R&D connections. Together, the companies aim to expand treatment options for millions living with metabolic disorders.
"We are excited to partner with OTR Therapeutics. The multi-program collaboration will expand our metabolic health pipeline into oral small-molecule therapeutics for targets where we have deep biological expertise, complementing our strong peptide R&D platform," said Utpal Singh, Chief Scientific Officer of Zealand Pharma.
"This partnership is an early testament - with more to follow - to the execution of our updated strategy to further strengthen and evolve our platform, broadening treatment options for people living with overweight, obesity, and other metabolic diseases. We are confident the partnership with OTR Therapeutics will be highly productive in achieving our shared goal of expanding treatment options for people living with metabolic diseases."
Zhui Chen, Founder and CEO of OTR Therapeutics, added, "We are thrilled to partner with Zealand Pharma, a company renowned for its legacy and expertise in metabolic diseases. This collaboration represents a strong endorsement of our proprietary platform and strategic vision, and our proven ability to drive innovation and deliver quality and speed in execution.
"By combining our strengths in innovative drug discovery and development with Zealand Pharma's deep expertise in the disease area, we are well positioned to discover potentially transformative therapies for patients worldwide."
